We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 10,000 results

  1. CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation

    Interleukin (IL-)23 is a major mediator and therapeutic target in chronic inflammatory diseases that also elicits tissue protection in the intestine...

    Anees Ahmed, Ann M. Joseph, ... Gregory F. Sonnenberg in Nature
    Article 12 June 2024

  2. Interleukin-12 and -23 Targeted Agents

    The role of the structurally related interleukin-(IL) 12 and IL-23, as key drivers of Th1 and Th17 differentiation, in the pathogenesis of...
    Mario Fernández-Ruiz in Infectious Complications in Biologic and Targeted Therapies
    Chapter 2022

  5. Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients

    Objectives

    Assessment of serum levels of IL-23 in PsA patients and its correlation with depression, anxiety, and disease activity.

    Methods ...
    Samar Abdalhamed Tabra, Salwa Elmorsy abd Elghany, ... Mohammed Hassan Abu-Zaid in Clinical Rheumatology
    Article Open access 21 July 2022

  6. Neuer Interleukin-23-Antikörper bei Morbus Crohn

    Robert Jänsch, Ulrike von Arnim in Gastro-News
    Article 17 April 2023

  8. Association of Interleukin 23 Receptor Polymorphisms with Predisposition to Rheumatoid Arthritis: An Updated Meta and Trial Sequential Analysis

    The etiology of Rheumatoid Arthritis (RA) development remained unclear, and several factors, such as environmental, genetic, and immune system...

    Surjyapratap Sarangi, Debashis Barik, ... Aditya K. Panda in Biochemical Genetics
    Article 25 January 2024

  9. Interleukin-23

    Christine Huppertz, Amanda Littlewood-Evans in Encyclopedia of Molecular Pharmacology
    Reference work entry 2021

  10. Interleukin-23

    Christine Huppertz, Amanda Littlewood-Evans in Encyclopedia of Molecular Pharmacology
    Living reference work entry 2021

  11. Association of interleukin-2, interleukin-21 and interleukin-23 with hyperlipidemia in pediatric type 1 diabetes

    Background

    In type 1 diabetes mellitus (T1DM), cytokines have a central role in orchestrating multicellular relations between β-cells and immune...

    Rehab G. Khalil, Adel Abdel-Moneim, ... Amr El-Sayed in Molecular Biology Reports
    Article 30 July 2021

  13. Interleukin-23 als neuer therapeutischer Angriffspunkt

    Andrea Warpakowski in Gastro-News
    Article 20 April 2022

  14. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)

    With the introduction of the latest class of biologic drugs targeting interleukin (IL)-23p19, three new, highly effective drugs can be used for the...

    T. Graier, W. Weger, ... Peter Wolf in Scientific Reports
    Article Open access 05 September 2022

  15. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

    Background

    Drug survival, defined as the length of time from initiation to discontinuation of a given therapy, allows comparisons between drugs, helps...

    Tiago Torres, Luis Puig, ... Andrea Chiricozzi in American Journal of Clinical Dermatology
    Article 17 August 2022

  16. Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities

    Psoriasis is an immune-mediated inflammatory skin disease associated with numerous inflammatory comorbidities, including increased cardiovascular...

    Alan Menter, Gerald G. Krueger, ... Richard G. Langley in Dermatology and Therapy
    Article Open access 29 January 2021

  17. The level of interleukin-17, 23, and gamma interferon in cutaneous leishmaniasis patients before and after intra lesion treatment

    Leishmaniasis is a zoonotic vector-borne disease that is endemic in tropical and sub-tropical districts. The immune system response is one of the...

    Mehdi Ghazanfari, Bahador Shahriari, ... Mohammad Hossein Motazedian in Journal of Parasitic Diseases
    Article 03 February 2022

  18. Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis

    Acetylcholine receptor (AChR) myasthenia gravis (MG) is a chronic autoimmune disease characterized by muscle weakness. The AChR + autoantibodies are...

    José A. Villegas, Jérôme Van Wassenhove, ... Nadine Dragin in Journal of Neuroinflammation
    Article Open access 13 January 2023

  19. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?

    There is substantial evidence regarding the association between psoriasis and the elevated risk of cardiovascular (CV) disease. Many patients with...

    Marianne de Brito, Zenas Z. N. Yiu in American Journal of Clinical Dermatology
    Article 22 July 2021

  20. Interleukin-23 instructs protective multifunctional CD4 T cell responses after immunization with the Mycobacterium tuberculosis subunit vaccine H1 DDA/TDB independently of interleukin-17A

    Abstract

    Interleukin (IL)-17A-producing T helper (Th)17 cells are increasingly being acknowledged to be associated with protective immunity to Mycobact...

    Kristina Ritter, Jochen Behrends, ... Christoph Hölscher in Journal of Molecular Medicine
    Article Open access 05 August 2021
Did you find what you were looking for? Share feedback.